Business UpdateJul 6, 2026, 07:07 AM
Regeneron Expects $127M IPR&D Charge, -$1.00 EPS Impact in Q2
AI Summary
Regeneron Pharmaceuticals expects to report an acquired in-process research and development (IPR&D) charge of approximately $127 million on a pre-tax basis for the second quarter of 2026. This charge, resulting from collaboration and licensing agreements, is anticipated to negatively impact both GAAP and non-GAAP net income per diluted share by about $1.00. The company emphasized that these preliminary estimates are unaudited and subject to finalization procedures.
Key Highlights
- Expects an acquired in-process research and development (IPR&D) charge of approximately $127 million pre-tax for Q2 2026.
- Charge stems from up-front and opt-in payments related to collaboration and licensing agreements.
- Anticipates a negative impact of approximately $1.00 on GAAP net income per diluted share for Q2 2026.
- Anticipates a negative impact of approximately $1.00 on non-GAAP net income per diluted share for Q2 2026.
- Preliminary estimates are subject to finalization and may differ from actual results.
Price Impact
More from REGN